| Oral chelation: should it be used with young children? | |
| | |
MedLine Citation:
|
PMID: 20806359 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Deferasirox, the only oral iron chelator approved in the US and Canada, achieved a pediatric label indication down to 2 years of age. FDA-mandated post-marketing safety surveillance in children under age 6 is ongoing. We wish to raise a non-safety-related concern with deferasirox chelation in very young children (2-5 years old). Specifically, the circumstances required for reliable daily ingestion of deferasirox do not mesh well with the developmental characteristics common in young children, which may limit adherence and cause parental distress. We review developmental challenges associated with oral chelation in this age group and provide suggestions to improve adherence in this population. |
| | |
Authors:
|
Lauren M Mednick; Jennifer Braunstein; Ellis Neufeld |
Related Documents
:
|
9169209 - Picture naming by young children: norms for name agreement, familiarity, and visual com... 9694309 - Differentiated ratings of perceived exertion at ventilatory threshold in children and a... 9243359 - Potentiation of mivacurium by rocuronium is age- and time-dependent: a study in childre... 18431949 - The end-state comfort effect in young children. 10775859 - Treatment of capillary hemangiomas of early childhood with a new method of cryosurgery. 22472239 - Juvenile-onset recurrent respiratory papillomatosis. 14628109 - Variations in diagnostic performances of dual-energy x-ray absorptiometry in the northw... 9293079 - Relationship between acute diarrhoea and low plasma levels of vitamin a and retinol bin... 17070729 - Detection and characterization of human group c rotavirus in the pediatric population o... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pediatric blood & cancer Volume: 55 ISSN: 1545-5017 ISO Abbreviation: Pediatr Blood Cancer Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-08-31 Completed Date: 2010-09-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101186624 Medline TA: Pediatr Blood Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 603-5 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Wiley-Liss, Inc. |
Affiliation:
|
Department of Psychiatry, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. Lauren.mednick@childrens.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Benzoic Acids
/
therapeutic use* Child, Preschool Drug Prescriptions Humans Iron Chelating Agents / therapeutic use* Medication Adherence Triazoles / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Benzoic Acids; 0/Iron Chelating Agents; 0/Triazoles; 0/deferasirox |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A Cre transgenic line for studying V2 neuronal lineages and functions in the spinal cord.
Next Document: Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarco...